RU2393160C2 - Фармацевтическая композиция, содержащая эфир темозоломида - Google Patents
Фармацевтическая композиция, содержащая эфир темозоломида Download PDFInfo
- Publication number
- RU2393160C2 RU2393160C2 RU2007114948/04A RU2007114948A RU2393160C2 RU 2393160 C2 RU2393160 C2 RU 2393160C2 RU 2007114948/04 A RU2007114948/04 A RU 2007114948/04A RU 2007114948 A RU2007114948 A RU 2007114948A RU 2393160 C2 RU2393160 C2 RU 2393160C2
- Authority
- RU
- Russia
- Prior art keywords
- carboxylate
- tmz
- acid
- methyl
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- -1 temozolomide ester Chemical class 0.000 title claims description 44
- 229960004964 temozolomide Drugs 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000000126 substance Substances 0.000 claims abstract description 17
- 230000002378 acidificating effect Effects 0.000 claims abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 31
- 239000011159 matrix material Substances 0.000 claims description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 20
- 239000002552 dosage form Substances 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 19
- 239000002775 capsule Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 230000000699 topical effect Effects 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000013270 controlled release Methods 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 12
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 12
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000005642 Oleic acid Substances 0.000 claims description 12
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 12
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 12
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000004530 micro-emulsion Substances 0.000 claims description 8
- 239000012071 phase Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000006211 transdermal dosage form Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000004800 polyvinyl chloride Substances 0.000 claims description 7
- 239000000829 suppository Substances 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 6
- 150000003333 secondary alcohols Chemical class 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 150000003509 tertiary alcohols Chemical class 0.000 claims description 6
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 235000010233 benzoic acid Nutrition 0.000 claims description 5
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 5
- 229960004488 linolenic acid Drugs 0.000 claims description 5
- 229920001296 polysiloxane Polymers 0.000 claims description 5
- 239000004334 sorbic acid Substances 0.000 claims description 5
- 235000010199 sorbic acid Nutrition 0.000 claims description 5
- 229940075582 sorbic acid Drugs 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- 235000011087 fumaric acid Nutrition 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 229940057995 liquid paraffin Drugs 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 229920000058 polyacrylate Polymers 0.000 claims description 4
- 229920002635 polyurethane Polymers 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- 239000005639 Lauric acid Substances 0.000 claims description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 229940031955 anhydrous lanolin Drugs 0.000 claims description 3
- 229960000541 cetyl alcohol Drugs 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- 235000021313 oleic acid Nutrition 0.000 claims description 3
- 235000019271 petrolatum Nutrition 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229940012831 stearyl alcohol Drugs 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 239000000006 Nitroglycerin Substances 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 238000007872 degassing Methods 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 210000002268 wool Anatomy 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- 235000004443 Ricinus communis Nutrition 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000012059 conventional drug carrier Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 27
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 25
- 201000009030 Carcinoma Diseases 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 201000001441 melanoma Diseases 0.000 description 11
- VVTMIOYTNALQAW-UHFFFAOYSA-N 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid Chemical class O=C1N(C)N=NC2=C(C(O)=O)N=CN21 VVTMIOYTNALQAW-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- 238000000132 electrospray ionisation Methods 0.000 description 8
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- OIMDZKSIZPZGLG-UHFFFAOYSA-N hexyl 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate Chemical compound N1=NN(C)C(=O)N2C1=C(C(=O)OCCCCCC)N=C2 OIMDZKSIZPZGLG-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 201000000849 skin cancer Diseases 0.000 description 5
- 201000008261 skin carcinoma Diseases 0.000 description 5
- DXVWMLQMDGMWEQ-UHFFFAOYSA-N 1h-imidazo[5,1-d][1,2,3,5]tetrazin-4-one Chemical class O=C1NN=NC2=CN=CN12 DXVWMLQMDGMWEQ-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- NAUUBFZMGPZOGO-UHFFFAOYSA-N cyclohexyl 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate Chemical compound N1=CN2C(=O)N(C)N=NC2=C1C(=O)OC1CCCCC1 NAUUBFZMGPZOGO-UHFFFAOYSA-N 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940035429 isobutyl alcohol Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- BYRHRROQTRHWEZ-UHFFFAOYSA-N 4-methylpentyl 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate Chemical compound N1=NN(C)C(=O)N2C1=C(C(=O)OCCCC(C)C)N=C2 BYRHRROQTRHWEZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- RINATXTXNBSCNL-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(C(C)CCC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(C(C)CCC)=NC(C(O)=O)=C21 RINATXTXNBSCNL-UHFFFAOYSA-N 0.000 description 2
- VLETYMFVTMEYSQ-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(C(C)CCCCC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(C(C)CCCCC)=NC(C(O)=O)=C21 VLETYMFVTMEYSQ-UHFFFAOYSA-N 0.000 description 2
- HETYFEXAKSQTRZ-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(C(C)CCCCCC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(C(C)CCCCCC)=NC(C(O)=O)=C21 HETYFEXAKSQTRZ-UHFFFAOYSA-N 0.000 description 2
- ZBDVQKIFAKJRIA-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(C(CC)CC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(C(CC)CC)=NC(C(O)=O)=C21 ZBDVQKIFAKJRIA-UHFFFAOYSA-N 0.000 description 2
- ZWYWJNNJDMEFSO-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(C(CC)CCC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(C(CC)CCC)=NC(C(O)=O)=C21 ZWYWJNNJDMEFSO-UHFFFAOYSA-N 0.000 description 2
- UAPUEWOTHBCJDJ-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(C(CC)CCCC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(C(CC)CCCC)=NC(C(O)=O)=C21 UAPUEWOTHBCJDJ-UHFFFAOYSA-N 0.000 description 2
- JZVOCWXVEIDPKQ-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(CC(C)CCCC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(CC(C)CCCC)=NC(C(O)=O)=C21 JZVOCWXVEIDPKQ-UHFFFAOYSA-N 0.000 description 2
- MYTIDZRTLCMVFY-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(CC(C)CCCCC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(CC(C)CCCCC)=NC(C(O)=O)=C21 MYTIDZRTLCMVFY-UHFFFAOYSA-N 0.000 description 2
- LSXUYFBTQKPPQI-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(CCC(C)CCC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(CCC(C)CCC)=NC(C(O)=O)=C21 LSXUYFBTQKPPQI-UHFFFAOYSA-N 0.000 description 2
- MSJZJGFKOCBIPK-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(CCC(C)CCCC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(CCC(C)CCCC)=NC(C(O)=O)=C21 MSJZJGFKOCBIPK-UHFFFAOYSA-N 0.000 description 2
- OUWQFPIRIMSIEW-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(CCCC(C)CC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(CCCC(C)CC)=NC(C(O)=O)=C21 OUWQFPIRIMSIEW-UHFFFAOYSA-N 0.000 description 2
- CNKJTIWECYGHSR-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(CCCC(C)CCC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(CCCC(C)CCC)=NC(C(O)=O)=C21 CNKJTIWECYGHSR-UHFFFAOYSA-N 0.000 description 2
- DFJTXRNLVIBASD-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(CCCCC(C)C)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(CCCCC(C)C)=NC(C(O)=O)=C21 DFJTXRNLVIBASD-UHFFFAOYSA-N 0.000 description 2
- KEPLFKCFJYVGLD-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(CCCCC(C)CC)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(CCCCC(C)CC)=NC(C(O)=O)=C21 KEPLFKCFJYVGLD-UHFFFAOYSA-N 0.000 description 2
- NNSJNKTXCXVMLK-UHFFFAOYSA-N N1=NN(C)C(=O)N2C(CCCCCC(C)C)=NC(C(O)=O)=C21 Chemical compound N1=NN(C)C(=O)N2C(CCCCCC(C)C)=NC(C(O)=O)=C21 NNSJNKTXCXVMLK-UHFFFAOYSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YTDPVQVGQALUMD-UHFFFAOYSA-N butyl 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate Chemical compound N1=NN(C)C(=O)N2C1=C(C(=O)OCCCC)N=C2 YTDPVQVGQALUMD-UHFFFAOYSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- MEGAXIXWEFNDMQ-UHFFFAOYSA-N ethyl 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate Chemical compound N1=NN(C)C(=O)N2C1=C(C(=O)OCC)N=C2 MEGAXIXWEFNDMQ-UHFFFAOYSA-N 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- KHALGYKGLMLQNN-UHFFFAOYSA-N heptyl 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate Chemical compound N1=NN(C)C(=O)N2C1=C(C(=O)OCCCCCCC)N=C2 KHALGYKGLMLQNN-UHFFFAOYSA-N 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- HRODEGJDQGRJSP-UHFFFAOYSA-N methyl 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate Chemical compound N1=NN(C)C(=O)N2C1=C(C(=O)OC)N=C2 HRODEGJDQGRJSP-UHFFFAOYSA-N 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- XPOXNEDSHNOIDE-UHFFFAOYSA-N octyl 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate Chemical compound N1=NN(C)C(=O)N2C1=C(C(=O)OCCCCCCCC)N=C2 XPOXNEDSHNOIDE-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- OCRRHQPAVWLVAG-UHFFFAOYSA-N pentyl 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate Chemical compound N1=NN(C)C(=O)N2C1=C(C(=O)OCCCCC)N=C2 OCRRHQPAVWLVAG-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- YDMIFDBNKQQFED-UHFFFAOYSA-N propyl 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate Chemical compound N1=NN(C)C(=O)N2C1=C(C(=O)OCCC)N=C2 YDMIFDBNKQQFED-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229940081995 fluorouracil injection Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- SYUXAJSOZXEFPP-UHFFFAOYSA-N glutin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccccc3OC4OC(CO)C(O)C(O)C4O SYUXAJSOZXEFPP-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940072981 nitro-dur Drugs 0.000 description 1
- 229940072992 nitrodisc Drugs 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- YOURXVGYNVXQKT-UHFFFAOYSA-N oxacycloundecane-2,11-dione Chemical compound O=C1CCCCCCCCC(=O)O1 YOURXVGYNVXQKT-UHFFFAOYSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410072056.4 | 2004-09-22 | ||
| CNA2004100720564A CN1752088A (zh) | 2004-09-22 | 2004-09-22 | 含有替莫唑胺酯的药用组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007114948A RU2007114948A (ru) | 2008-10-27 |
| RU2393160C2 true RU2393160C2 (ru) | 2010-06-27 |
Family
ID=36089840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007114948/04A RU2393160C2 (ru) | 2004-09-22 | 2005-09-15 | Фармацевтическая композиция, содержащая эфир темозоломида |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7579336B2 (enExample) |
| EP (1) | EP1798234B1 (enExample) |
| JP (2) | JP5620046B2 (enExample) |
| KR (1) | KR101065984B1 (enExample) |
| CN (1) | CN1752088A (enExample) |
| AR (1) | AR050947A1 (enExample) |
| AU (1) | AU2005287799B2 (enExample) |
| BR (1) | BRPI0515555A (enExample) |
| CA (1) | CA2580910C (enExample) |
| DK (1) | DK1798234T3 (enExample) |
| ES (1) | ES2389376T3 (enExample) |
| IL (1) | IL182027A (enExample) |
| MX (1) | MX2007003366A (enExample) |
| MY (1) | MY153713A (enExample) |
| NZ (1) | NZ554609A (enExample) |
| PL (1) | PL1798234T3 (enExample) |
| RU (1) | RU2393160C2 (enExample) |
| UA (1) | UA89795C2 (enExample) |
| WO (1) | WO2006032190A1 (enExample) |
| ZA (1) | ZA200702801B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2818486C1 (ru) * | 2020-04-13 | 2024-05-02 | Кеайсе Медисин Ухань Корп. | Арил-конденсированное соединение изоселеназола, содержащее тетразиновый заместитель, способ его получения и его применение |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1727340B (zh) * | 2004-07-29 | 2011-05-18 | 天津帝士力投资控股集团有限公司 | 一种替莫唑胺-8-羧酸酯及其组合物 |
| EP1808173A1 (en) * | 2006-01-12 | 2007-07-18 | Matthias Dormeyer | Use of CNS penetrating anticancer compounds for the treatment of protozan diseases |
| US8558511B2 (en) * | 2009-04-07 | 2013-10-15 | Battelle Memorial Institute | Method and apparatus for smart battery charging including a plurality of controllers each monitoring input variables |
| KR20140087846A (ko) * | 2012-12-31 | 2014-07-09 | 주식회사 삼양바이오팜 | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 |
| RU2527258C1 (ru) * | 2013-02-19 | 2014-08-27 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | 6-ЗАМЕЩЕННЫЕ 3-АЗОЛИЛИМИДАЗО[1,2-b][1,2,4,5]ТЕТРАЗИНЫ, ПРОЯВЛЯЮЩИЕ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ |
| US10709715B2 (en) * | 2017-12-03 | 2020-07-14 | Cipla Limited | Method of treating hypertension |
| CN113271939B (zh) * | 2018-08-09 | 2025-03-07 | 伊利诺伊大学董事会 | 咪唑四嗪化合物 |
| CN114014862A (zh) * | 2021-06-28 | 2022-02-08 | 烟台大学 | 一种治疗脑胶质瘤的新化合物及其制备和应用 |
| CN116947765B (zh) * | 2022-06-23 | 2025-10-10 | 北京新源医疗有限责任公司 | 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0252682A2 (en) * | 1986-07-02 | 1988-01-13 | May & Baker Limited | Tetrazines |
| RU2148401C1 (ru) * | 1993-01-13 | 2000-05-10 | Канзер Рисерч Кампейн Технолоджи, Лтд. | Фармацевтическая композиция с антиопухолевой активностью и способ ее получения |
| CN1485327A (zh) * | 2002-09-29 | 2004-03-31 | 天津天士力集团有限公司 | 替莫唑胺-8-羧酸脂和-8-酰胺衍生物，它们的合成方法以及它们在制备抗癌制剂中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1742723A (zh) * | 2004-09-02 | 2006-03-08 | 天津倍方科技发展有限公司 | 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途 |
-
2004
- 2004-09-22 CN CNA2004100720564A patent/CN1752088A/zh active Pending
-
2005
- 2005-09-15 ES ES05785075T patent/ES2389376T3/es not_active Expired - Lifetime
- 2005-09-15 RU RU2007114948/04A patent/RU2393160C2/ru not_active IP Right Cessation
- 2005-09-15 US US11/575,849 patent/US7579336B2/en not_active Expired - Fee Related
- 2005-09-15 MX MX2007003366A patent/MX2007003366A/es active IP Right Grant
- 2005-09-15 CA CA2580910A patent/CA2580910C/en not_active Expired - Fee Related
- 2005-09-15 NZ NZ554609A patent/NZ554609A/en not_active IP Right Cessation
- 2005-09-15 BR BRPI0515555-0A patent/BRPI0515555A/pt not_active IP Right Cessation
- 2005-09-15 UA UAA200704418A patent/UA89795C2/ru unknown
- 2005-09-15 KR KR1020077009054A patent/KR101065984B1/ko not_active Expired - Fee Related
- 2005-09-15 DK DK05785075.2T patent/DK1798234T3/da active
- 2005-09-15 WO PCT/CN2005/001477 patent/WO2006032190A1/zh not_active Ceased
- 2005-09-15 EP EP05785075A patent/EP1798234B1/en not_active Expired - Lifetime
- 2005-09-15 AU AU2005287799A patent/AU2005287799B2/en not_active Ceased
- 2005-09-15 PL PL05785075T patent/PL1798234T3/pl unknown
- 2005-09-15 JP JP2007532748A patent/JP5620046B2/ja not_active Expired - Fee Related
- 2005-09-21 AR ARP050103949A patent/AR050947A1/es not_active Application Discontinuation
- 2005-09-22 MY MYPI20054428A patent/MY153713A/en unknown
-
2007
- 2007-03-19 IL IL182027A patent/IL182027A/en not_active IP Right Cessation
- 2007-04-03 ZA ZA200702801A patent/ZA200702801B/xx unknown
-
2012
- 2012-09-24 JP JP2012209183A patent/JP2013028630A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0252682A2 (en) * | 1986-07-02 | 1988-01-13 | May & Baker Limited | Tetrazines |
| RU2148401C1 (ru) * | 1993-01-13 | 2000-05-10 | Канзер Рисерч Кампейн Технолоджи, Лтд. | Фармацевтическая композиция с антиопухолевой активностью и способ ее получения |
| CN1485327A (zh) * | 2002-09-29 | 2004-03-31 | 天津天士力集团有限公司 | 替莫唑胺-8-羧酸脂和-8-酰胺衍生物，它们的合成方法以及它们在制备抗癌制剂中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| Wang Yongfeng et al, 1997, J.Org. Chem, 62, 7288-7294. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2818486C1 (ru) * | 2020-04-13 | 2024-05-02 | Кеайсе Медисин Ухань Корп. | Арил-конденсированное соединение изоселеназола, содержащее тетразиновый заместитель, способ его получения и его применение |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080044457A1 (en) | 2008-02-21 |
| MX2007003366A (es) | 2008-03-05 |
| AU2005287799A1 (en) | 2006-03-30 |
| BRPI0515555A (pt) | 2008-07-29 |
| JP2008513523A (ja) | 2008-05-01 |
| EP1798234A4 (en) | 2009-04-29 |
| RU2007114948A (ru) | 2008-10-27 |
| CA2580910A1 (en) | 2006-03-30 |
| JP2013028630A (ja) | 2013-02-07 |
| IL182027A (en) | 2014-05-28 |
| ES2389376T3 (es) | 2012-10-25 |
| JP5620046B2 (ja) | 2014-11-05 |
| PL1798234T3 (pl) | 2012-11-30 |
| EP1798234B1 (en) | 2012-06-13 |
| WO2006032190A1 (en) | 2006-03-30 |
| MY153713A (en) | 2015-03-13 |
| KR101065984B1 (ko) | 2011-09-19 |
| CA2580910C (en) | 2011-10-25 |
| IL182027A0 (en) | 2007-07-24 |
| UA89795C2 (ru) | 2010-03-10 |
| AU2005287799B2 (en) | 2009-03-26 |
| HK1100440A1 (en) | 2007-09-21 |
| CN1752088A (zh) | 2006-03-29 |
| US7579336B2 (en) | 2009-08-25 |
| ZA200702801B (en) | 2008-08-27 |
| KR20070062569A (ko) | 2007-06-15 |
| DK1798234T3 (da) | 2012-08-27 |
| AR050947A1 (es) | 2006-12-06 |
| NZ554609A (en) | 2010-06-25 |
| EP1798234A1 (en) | 2007-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11820751B2 (en) | Urolithin derivatives and methods of use thereof | |
| JP2013028630A (ja) | テモゾロマイドエステルよりなる医薬組成物 | |
| CN101624376B (zh) | 取代酰肼类化合物及其应用 | |
| CN110041342B (zh) | 一种含硒化合物及其用途 | |
| JP5701387B2 (ja) | ベルバミンのジカルボキシミド誘導体、その調製方法及び使用 | |
| CN118290384B (zh) | 大豆苷元与哌嗪共晶物及制备方法和其组合物与用途 | |
| WO2006024238A1 (en) | The pharmaceutical composition containing temozolomide-8-carboxylic esters and the use of the temozolomide-8-carboxylic esters for manufacture of the anti-tumour medicine | |
| CN101863901A (zh) | 2-(取代苯基)-2-(4,5,6,7-四氢噻吩并[3,2-c]吡啶-5(4H)-基)-N-取代-乙酰胺、其制备方法和用途 | |
| KR19980702374A (ko) | 무정형 피레타나이드, 피레타나이드 동소체, 이의 제조방법 및 이의 용도 | |
| KR20110118145A (ko) | 조성물 및 이의 이용방법 | |
| CN109134470B (zh) | 一种含硒化合物及其用途 | |
| HK1100440B (en) | Pharmaceutical composition comprising temozolomide ester | |
| CN101805355B (zh) | 一类噻吩并吡啶酮衍生物、其制备方法和用途 | |
| CN117777056A (zh) | 异阿魏酸哌嗪盐及其制备方法和药物组合物与用途 | |
| CN107266468A (zh) | 含吡唑啉结构的噻喃并嘧啶类化合物的制备及应用 | |
| CN111138282A (zh) | 绿原酸l-精氨酸盐及其用途 | |
| WO2022122042A1 (zh) | 阿比特龙衍生物及其制备方法 | |
| TWI535725B (zh) | 用以治療發炎和／或腫瘤的新穎倍半萜類化合物之衍生物及包含此新穎倍半萜類化合物之衍生物的組合物 | |
| CN102417514B (zh) | 吡啶衍生物、其制备方法和用途 | |
| CN118420586A (zh) | 二氢槲皮素与吡啶甲酸共晶及制备方法和其药物组合物与用途 | |
| CN110938001A (zh) | 绿原酸乙醇胺盐及用途 | |
| WO2013107278A1 (zh) | 酮类与吲哚衍生物反应合成的新型抗癌化合物 | |
| JPH03170477A (ja) | プロテインキナーゼｃ阻害剤として有用なピリジニルオキサゾール―２―オン類 | |
| WO2019070698A1 (en) | Novel forms of ibrutinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170916 |